In biochemistry and pharmacology, a ligand is a substance that forms a complex with a biomolecule to serve a biological purpose. In protein-ligand binding, the ligand is usually a molecule which produces a signal by binding to a site on a target protein. The binding typically results in a change of conformation of the target protein. In DNA-ligand binding studies, the ligand can be a small molecule, ion,[1] or protein[2] which binds to the DNA double helix. The relationship between ligand and binding partner is a function of charge, hydrophobicity, and molecular structure. The instance of binding occurs over an infinitesimal range of time and space, so the rate constant is usually a very small number.
Binding occurs by intermolecular forces, such as ionic bonds, hydrogen bonds and Van der Waals forces. The association of docking is actually reversible through dissociation. Measurably irreversible covalent bonding between a ligand and target molecule is atypical in biological systems. In contrast to the definition of ligand in metalorganic and inorganic chemistry, in biochemistry it is ambiguous whether the ligand generally binds at a metal site, as is the case in hemoglobin. In general, the interpretation of ligand is contextual with regards to what sort of binding has been observed. The etymology stems from ligare, which means 'to bind'.
Ligand binding to a receptor protein alters the chemical conformation by affecting the three-dimensional shape orientation. The conformation of a receptor protein composes the functional state. Ligands include substrates, inhibitors, activators, and neurotransmitters. The rate of binding is called affinity, and this measurement typifies a tendency or strength of the effect. Binding affinity is actualized not only by host-guest interactions, but also by solvent effects that can play a dominant, steric role which drives non-covalent binding in solution.[3] The solvent provides a chemical environment for the ligand and receptor to adapt, and thus accept or reject each other as partners.
Radioligands are radioisotope labeled compounds used in vivo as tracers in PET studies and for in vitro binding studies.
The interaction of most ligands with their binding sites can be characterized in terms of a binding affinity. In general, high-affinity ligand binding results from greater intermolecular force between the ligand and its receptor while low-affinity ligand binding involves less intermolecular force between the ligand and its receptor. In general, high-affinity binding results in a higher degree of occupancy for the ligand at its receptor binding site than is the case for low-affinity binding; the residence time (lifetime of the receptor-ligand complex) does not correlate. High-affinity binding of ligands to receptors is often physiologically important when some of the binding energy can be used to cause a conformational change in the receptor, resulting in altered behavior of an associated ion channel or enzyme.
A ligand that can bind to a receptor, alter the function of the receptor, and trigger a physiological response is called an agonist for that receptor. Agonist binding to a receptor can be characterized both in terms of how much physiological response can be triggered and in terms of the concentration of the agonist that is required to produce the physiological response. High-affinity ligand binding implies that a relatively low concentration of a ligand is adequate to maximally occupy a ligand-binding site and trigger a physiological response. The lower the Ki concentration is, the more likely there will be a chemical reaction between the pending ion and the receptive antigen. Low-affinity binding (high Ki level) implies that a relatively high concentration of a ligand is required before the binding site is maximally occupied and the maximum physiological response to the ligand is achieved. In the example shown to the right, two different ligands bind to the same receptor binding site. Only one of the agonists shown can maximally stimulate the receptor and, thus, can be defined as a full agonist. An agonist that can only partially activate the physiological response is called a partial agonist. In this example, the concentration at which the full agonist (red curve) can half-maximally activate the receptor is about 5 x 109 Molar (nM = nanomolar). Ligands that bind to a receptor but fail to activate the physiological response are receptor antagonists.
In the example shown to the left, ligand-binding curves are shown for two ligands with different binding affinities. Ligand binding is often characterized in terms of the concentration of ligand at which half of the receptor binding sites are occupied, known as the IC50, which is related to but different from the dissociation constant. The ligand illustrated by the red curve has a higher binding affinity and smaller Kd than the ligand illustrated by the green curve. If these two ligands were present at the same time, more of the higher-affinity ligand would be bound to the available receptor binding sites. This is how carbon monoxide can compete with oxygen in binding to hemoglobin, resulting in carbon monoxide poisoning.
Binding affinity is most commonly determined using a radiolabeled ligand, known as a tagged ligand. Homologous competitive binding experiments involve binding competition between a tagged ligand and an untagged ligand.[4] Real-time based methods, which are often label-free, such as surface plasmon resonance, dual polarization interferometry and Multi-Parametric Surface Plasmon Resonance (MP-SPR) can not only quantify the affinity from concentration based assays; but also from the kinetics of association and dissociation, and in the later cases, the conformational change induced upon binding. MP-SPR also enables measurements in high saline dissociation buffers thanks to a unique optical setup. Microscale Thermophoresis (MST), an immobilization-free method[5] was developed. This method allows the determination of the binding affinity without any limitation to the ligand's molecular weight.[6]
For the use of statistical mechanics in a quantitative study of the ligand-receptor binding affinity, see the comprehensive article[7] on the configurational partition function.
Binding affinity data alone does not determine the overall potency of a drug. Potency is a result of the complex interplay of both the binding affinity and the ligand efficacy. Ligand efficacy refers to the ability of the ligand to produce a biological response upon binding to the target receptor and the quantitative magnitude of this response. This response may be as an agonist, antagonist, or inverse agonist, depending on the physiological response produced.[8]
Selective ligands have a tendency to bind to very limited kinds of receptor, whereas non-selective ligands bind to several types of receptors. This plays an important role in pharmacology, where drugs that are non-selective tend to have more adverse effects, because they bind to several other receptors in addition to the one generating the desired effect.
Bivalent ligands consist of two drug-like molecules (pharmacophores or ligands) connected by an inert linker. There are various kinds of bivalent ligands and are often classified based on what the pharmacophores target. Homobivalent ligands target two of the same receptor types. Heterobivalent ligands target two different receptor types.[9] Bitopic ligands target an orthosteric binding sites and allosteric binding sites on the same receptor.[10]
In scientific research, bivalent ligands have been used to study receptor dimers and to investigate their properties. This class of ligands was pioneered by Philip S. Portoghese and coworkers while studying the opioid receptor system.[11][12][13] Bivalent ligands were also reported early on by Micheal Conn and coworkers for the gonadotropin-releasing hormone receptor.[14][15] Since these early reports, there have been many bivalent ligands reported for various GPCR systems including cannabinoid,[16] serotonin,[17][18] oxytocin,[19] and melanocortin receptor systems,[20][21][22] and for GPCR-LIC systems (D2 and nACh receptors).[9]
Bivalent ligands usually tend to be larger than their monovalent counterparts, and therefore, not drug-like. (See Lipinskis rule of five.) Many believe this limits their applicability in clinical settings.[23][24] In spite of these beliefs, there have been many ligands that have reported successful pre-clinical animal studies.[21][22][19][25][26][27] Given that some bivalent ligands can have many advantages compared to their monovalent counterparts (such as tissue selectivity, increased binding affinity, and increased potency or efficacy), bivalents may offer some clinical advantages as well.
A privileged scaffold[28] is a molecular framework or chemical moiety that is statistically recurrent among known drugs or among a specific array of biologically active compounds. These privileged elements[29] can be used as a basis for designing new active biological compounds or compound libraries.
Main methods to study proteinligand interactions are principal hydrodynamic and calorimetric techniques, and principal spectroscopic and structural methods such as
Other techniques include: fluorescence intensity, bimolecular fluorescence complementation, FRET (fluorescent resonance energy transfer) / FRET quenching surface plasmon resonance, bio-layer interferometry, Coimmunopreciptation indirect ELISA, equilibrium dialysis, gel electrophoresis, far western blot, fluorescence polarization anisotropy, electron paramagnetic resonance, microscale thermophoresis
The dramatically increased computing power of supercomputers and personal computers has made it possible to study proteinligand interactions also by means of computational chemistry. For example, a worldwide grid of well over a million ordinary PCs was harnessed for cancer research in the project grid.org, which ended in April 2007. Grid.org has been succeeded by similar projects such as World Community Grid, Human Proteome Folding Project, Compute Against Cancer and Folding@Home.
Read more here:
Ligand (biochemistry) - Wikipedia
- Ofquack to regulate herbal medicine? [Last Updated On: August 17th, 2024] [Originally Added On: April 6th, 2010]
- The FIH have appointed a (former?) supporter of AIDS denialism as Chief Executive [Last Updated On: August 17th, 2024] [Originally Added On: April 12th, 2010]
- Back Quacks Whacked, Singh Wins [Last Updated On: August 17th, 2024] [Originally Added On: April 16th, 2010]
- Financial irregularities at the FIH? [Last Updated On: August 17th, 2024] [Originally Added On: April 21st, 2010]
- Statement from the Society of Homeopaths on the departure of Paula Ross [Last Updated On: August 17th, 2024] [Originally Added On: April 24th, 2010]
- Voting [Last Updated On: August 17th, 2024] [Originally Added On: May 6th, 2010]
- Why am I using posterous and where will you find it on my blog? [Last Updated On: August 17th, 2024] [Originally Added On: May 22nd, 2010]
- Paranoia, conspiracies and leaks – are you now, or have you ever been a homeopath? [Last Updated On: August 17th, 2024] [Originally Added On: May 29th, 2010]
- David Tredinnick in quacks for questions [Last Updated On: August 17th, 2024] [Originally Added On: June 3rd, 2010]
- The lurking fear in Tredinnick’s Integrated Health Care debate [Last Updated On: August 17th, 2024] [Originally Added On: June 9th, 2010]
- Homeopathic Action Trust still funding unethical trials [Last Updated On: August 17th, 2024] [Originally Added On: June 12th, 2010]
- Sikora & al-Megrahi [Last Updated On: August 17th, 2024] [Originally Added On: July 17th, 2010]
- Insurance giants sponsor seminar by delusional homeopath [Last Updated On: August 17th, 2024] [Originally Added On: July 27th, 2010]
- Dore are in financial trouble – again [Last Updated On: August 17th, 2024] [Originally Added On: August 4th, 2010]
- Karol Sikora is a very confused man [Last Updated On: August 17th, 2024] [Originally Added On: August 17th, 2010]
- Politicians, their babies & MMR [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Farewell to the RLHH, hello to the RLHIM [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Homeopathy and the NHS in Scotland [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- The UKIP MEP and Andrew Wakefield [Last Updated On: August 17th, 2024] [Originally Added On: October 13th, 2010]
- NICE & the Cancer Drugs Fund – politics based medicine [Last Updated On: August 17th, 2024] [Originally Added On: November 7th, 2010]
- The Nobel Prize winner and the unethical autism trial [Last Updated On: August 17th, 2024] [Originally Added On: December 11th, 2010]
- Homeopaths respond to the Abha Light Scandal [Last Updated On: August 17th, 2024] [Originally Added On: May 15th, 2011]
- Brian Haw and the false cures of quackery [Last Updated On: August 17th, 2024] [Originally Added On: June 19th, 2011]
- Prince Charles congratulates homeopaths who try to treat AIDS with homeopathy [Last Updated On: August 17th, 2024] [Originally Added On: July 3rd, 2011]
- Intro to Biochemistry 4130 [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- Aging and Rejuvenation: Chemistry and Biochemistry at Work [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- General Biochemistry Review [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- Wu Tang - Biochemical Equation (Datsik [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- Biochemistry Proves The Existence of God [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- MF DOOM ft RZA Biochemical Equation [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- Biochemistry- Clemson Graduate School [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- Ch 2 Water (Biochemistry) [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- Carbohydrates - Biochemistry [Last Updated On: August 31st, 2011] [Originally Added On: August 31st, 2011]
- Introduction to Biochemistry Lecture 1 of 4 [Last Updated On: August 31st, 2011] [Originally Added On: August 31st, 2011]
- Nerdcore Biochemistry Hip Hop [Last Updated On: September 17th, 2011] [Originally Added On: September 17th, 2011]
- Bite-Sized Biochemistry #16: Carbohydrates I (Structure and Function) [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Biochemistry the Movie Part 2 [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Ch 17 Beta Oxidation part 1 (Biochemistry) [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Introduction to Biochemistry Lecture 2 of 4 [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Bite-Sized Biochemistry #3: Protein Structure I [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Bite-Sized Biochemistry #19: Cellular Signaling II [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Ch 21 Fatty Acid Synthesis part 1(Biochemistry) [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Ch 5 Hemoglobin part 1 (Biochemistry) [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Seminar Profiles - BSc Sport [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Get to Grips with Biochemistry (Glycolysis - Part 1) [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Cytochrome P450: Radicals in a Biochemical Setting [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Biochemistry and Biophysics Career Overview [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- PHYSIOLOGY AND BIOCHEMISTRY OF ANIMAL FOODS 101 (Cholesterol, Saturated Fat, Etc) #319 [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Ch 3 Amino Acids part 1 (Biochemistry) [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Biochemistry the Movie Part 1 [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Smith: General, Organic, [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Bite-Sized Biochemistry #53 - Immune System [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Six Degrees: from Kevin Bacon to Biochemistry [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Introduction to Biochemistry [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- DUBSurce - Biochemical eagles [FREE DOWNLOAD] [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Ch 15 Glycolysis Regulation part 4 (Biochemistry) [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Human Biochemistry - Allosteric Enzymes [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Water, Acids, and Buffers in Biochemistry, Part 1 of 8 [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- The Work of a Clinical Biochemistry Laboratory (Part 1 of 2) [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Krebs Cycle Song: Musical Biochemistry! [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Ch 3 Amino Acids part 2 (Biochemistry) [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Alcohol Fermentation and the Dawn of Biochemistry [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Ch 4 Protein Structure part 1 (Biochemistry) [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Bite-Sized Biochemistry #45 - Transcription I (RNA Synthesis) [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- Kaplan's USMLE Step 1 Program Preview: Biochemistry [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- Bite-Sized Biochemistry #47 - Transcription III / Translation I [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Bite-Sized Biochemistry #22 - Glycolysis II / Carbohydrate Metabolism [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Bite-Sized Biochemistry #39 - Nucleotide Metabolism I [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Bite-Sized Biochemistry #48 - Translation II (Protein Synthesis) [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Biochemical tests of bacteria [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Chinese Crossfire - Biochemical Desert [De_Dust2] [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- Holistic Biochemistry of Cannabinoids by Robert Melamede (part 1 of 5) [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Ch 12 Signaling part 1(Biochemistry) [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Bite-Sized Biochemistry #8: Protein Structure and Hemoglobin [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- I Love My Major: Biochemistry [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- A biochemical rheostat controls cell death using protein-protein interaction Bim Mcl1 [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Lecture - 4 Protein structure II [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Bite-Sized Biochemistry #1: Basics [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Scope of Biochemistry - Will I get a job ? [Last Updated On: October 9th, 2011] [Originally Added On: October 9th, 2011]
- Scope of Biochemistry - Will I get a job ? [Last Updated On: August 17th, 2024] [Originally Added On: October 9th, 2011]